Entera Bio Ltd. Dividend per Share

Dividend per Share of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Dividend per Share growth rates and interactive chart. Total amount of dividends paid in a quarter or a year divided by the weighted average number of shares outstanding. Can be easily compared to the share price, to determine how much in dividends is an investor getting for each $1 paid for a stock.


Highlights and Quick Summary

  • Dividend per Share for the quarter ending June 29, 2020 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Dividend per Share decreased by NaN%
  • Annual Dividend per Share for 2019 was 0.0 (a NaN% decrease from previous year)
  • Annual Dividend per Share for 2018 was 0.0 (a NaN% decrease from previous year)
  • Twelve month Dividend per Share ending June 29, 2020 was 0.0 (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Dividend per Share decreased by NaN% year-over-year
Trailing Dividend per Share for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
0.0 0.0 0.0 0.0
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Dividend per Share of Entera Bio Ltd.

Most recent Dividend per Shareof ENTX including historical data for past 10 years.

Interactive Chart of Dividend per Share of Entera Bio Ltd.

Entera Bio Ltd. Dividend per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.